An ionic liquid nanoemulsion transdermal delivery system for targeted melanoma therapy

Area of Science:

• Oncology
• Dermatology
• Nanotechnology
• Pharmacology

Background:

• Melanoma poses a significant challenge due to limitations in current transdermal treatment efficacy.
• Achieving effective drug concentrations in deep tumors and improving percutaneous penetration remain critical issues.

Purpose of the Study:

• To design and synthesize novel dacarbazine/benzothiocycloheptane couplets for enhanced melanoma treatment.
• To develop and evaluate a transdermal drug delivery system for improved percutaneous delivery of anti-melanoma agents.

Main Methods:

• Synthesis of dacarbazine/benzothiocycloheptane couplets, including compound HIT-1.
• Preparation and characterization of self-assembled nanoemulsions (HIT-1/PM-MEs) using molecular simulation.
• In vitro cytotoxicity assays, cell cycle analysis, and gene/protein expression studies.
• In vivo evaluation of transdermal delivery system's antitumor effects and immune response stimulation.

Main Results:

• Compound HIT-1 demonstrated significant cytotoxicity against B16-F10 melanoma cells, exceeding that of dacarbazine (DTIC).
• HIT-1 induced apoptosis and G0/G1 phase arrest in melanoma cells.
• The optimized nanoemulsion, HIT-1/PM-ME-1-1, exhibited superior transdermal delivery and anti-melanoma activity compared to DTIC.
• HIT-1/PM-ME-1-1 modulated key gene and protein expressions related to apoptosis and cellular stress.
• The transdermal system demonstrated optimal antitumor effects and stimulated an antitumor immune response.

Conclusions:

• The synthesized compound HIT-1 and its nanoemulsion formulation represent a promising advancement in melanoma therapy.
• The developed transdermal drug delivery system offers a valuable new strategy for treating cutaneous melanoma with improved efficacy and delivery.
• This approach addresses the critical need for enhanced drug penetration and concentration in deep-seated melanoma tumors.